Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Aug 14, 2024

SELL
$0.0 - $228.9 $0 - $147,182
-643 Closed
0 $0
Q3 2023

Aug 14, 2024

BUY
$191.51 - $216.16 $957 - $1,080
5 Added 0.78%
643 $136 Million
Q2 2023

Aug 14, 2024

BUY
$187.64 - $206.25 $12,759 - $14,025
68 Added 11.93%
638 $123 Million
Q1 2023

Aug 14, 2024

SELL
$127.59 - $203.08 $15,438 - $24,572
-121 Reduced 17.51%
570 $115 Million
Q4 2022

Aug 14, 2024

SELL
$117.37 - $139.17 $6,924 - $8,211
-59 Reduced 7.87%
691 $88.8 Million
Q2 2022

Aug 14, 2024

BUY
$108.81 - $179.33 $53,208 - $87,692
489 Added 187.36%
750 $133 Million
Q1 2022

Aug 14, 2024

BUY
$119.61 - $157.85 $31,218 - $41,198
261 New
261 $37.6 Million
Q4 2021

Aug 30, 2024

SELL
$142.57 - $190.86 $309,804 - $414,738
-2,173 Reduced 89.28%
261 $40.3 Million
Q3 2021

Aug 30, 2024

BUY
$142.45 - $169.82 $8,547 - $10,189
60 Added 2.53%
2,434 $413 Million
Q2 2021

Aug 30, 2024

BUY
$135.08 - $161.1 $320,679 - $382,451
2,374 New
2,374 $374 Million
Q1 2021

Aug 30, 2024

SELL
$137.51 - $190.8 $4.27 Million - $5.92 Million
-31,032 Reduced 92.89%
2,374 $330 Million
Q4 2020

Aug 30, 2024

BUY
$164.63 - $211.93 $5.5 Million - $7.08 Million
33,406 New
33,406 $5.85 Billion

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.